Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
BMIQ11
MCID: BDY004
MIFTS: 78

Body Mass Index Quantitative Trait Locus 11 (BMIQ11)

Categories: Bone diseases, Endocrine diseases, Genetic diseases, Metabolic diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Body Mass Index Quantitative Trait Locus 11

About this section

MalaCards integrated aliases for Body Mass Index Quantitative Trait Locus 11:

Name: Body Mass Index Quantitative Trait Locus 11 57 29 40
Obesity 57 12 74 29 55 6 43 44 15 40 17 72 33
Obesity, Early-Onset, Susceptibility to 57 6
Obesity, Severe, and Type Ii Diabetes 57 6
Obesity, Susceptibility to, Bmiq11 57 13
Obesity, Mild, Early-Onset 57 6
Obesity, Association with 57 6
Obesity, Late-Onset 57 6
Obesity Due to Melanocortin 4 Receptor Deficiency 59
Obesity , Susceptibility to 6
Obesity, Susceptibility to 57
Obesity, Early-Onset 57
Mc4r Deficiency 59
Obesity, Severe 57
Obesity Bmiq11 57
Bmiq11 57

Characteristics:

Orphanet epidemiological data:

59
obesity due to melanocortin 4 receptor deficiency
Inheritance: Autosomal dominant,Autosomal recessive; Prevalence: 1-5/10000 (France); Age of onset: Infancy,Neonatal;

HPO:

32
obesity:
Inheritance autosomal dominant inheritance autosomal recessive inheritance polygenic inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Metabolic diseases Rare diseases
Anatomical: Endocrine diseases Bone diseases
See all MalaCards categories (disease lists)
ICD10: 33 34
Orphanet: 59  
Rare endocrine diseases


External Ids:

Disease Ontology 12 DOID:9970
ICD9CM 35 278.00
MeSH 44 D009765
NCIt 50 C3283
SNOMED-CT 68 5476005
ICD10 33 E66 E66.0 E66.9
ICD10 via Orphanet 34 E66.8
Orphanet 59 ORPHA71529
UMLS 72 C0028754
Sources

Summaries for Body Mass Index Quantitative Trait Locus 11

About this section
MedlinePlus : 43 Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person's weight is greater than what's considered healthy for his or her height. Obesity happens over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active. Obesity increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. If you have obesity, losing even 5 to 10 percent of your weight can delay or prevent some of these diseases. For example, that means losing 10 to 20 pounds if you weigh 200 pounds. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Body Mass Index Quantitative Trait Locus 11, also known as obesity, is related to diabetes mellitus, noninsulin-dependent and prader-willi syndrome, and has symptoms including symptoms, high weight and obesity, metabolically benign. An important gene associated with Body Mass Index Quantitative Trait Locus 11 is UCP3 (Uncoupling Protein 3), and among its related pathways/superpathways are Glucose / Energy Metabolism and Circadian rythm related genes. The drugs Oseltamivir and Citalopram have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and breast, and related phenotypes are increased adipose tissue and polyphagia

Disease Ontology : 12 An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has material basis in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness.

UniProtKB/Swiss-Prot : 74 Obesity: A condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.

More information from OMIM: 300306 601665
Sources

Related Diseases for Body Mass Index Quantitative Trait Locus 11

About this section

Diseases in the Body Mass Index Quantitative Trait Locus 11 family:

Body Mass Index Quantitative Trait Locus 9 Body Mass Index Quantitative Trait Locus 8
Body Mass Index Quantitative Trait Locus 1 Body Mass Index Quantitative Trait Locus 2
Body Mass Index Quantitative Trait Locus 3 Body Mass Index Quantitative Trait Locus 4
Body Mass Index Quantitative Trait Locus 10 Body Mass Index Quantitative Trait Locus 7
Body Mass Index Quantitative Trait Locus 5 Body Mass Index Quantitative Trait Locus 6
Body Mass Index Quantitative Trait Locus 12 Body Mass Index Quantitative Trait Locus 13
Body Mass Index Quantitative Trait Locus 14 Body Mass Index Quantitative Trait Locus 15
Body Mass Index Quantitative Trait Locus 18 Body Mass Index Quantitative Trait Locus 19
Body Mass Index Quantitative Trait Locus 20

Diseases related to Body Mass Index Quantitative Trait Locus 11 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2064)
# Related Disease Score Top Affiliating Genes
1 diabetes mellitus, noninsulin-dependent 34.6 UCP3 PRMT7 PPARG MC4R GHRL ENPP1
2 prader-willi syndrome 34.3 POMC MC4R GHRL AGRP
3 eating disorder 34.0 POMC MC4R GHRL
4 glucose intolerance 34.0 PPARG GHRL ADRB3
5 pseudohypoparathyroidism, type ic 33.3 MC4R GNAS
6 overnutrition 33.1 UCP3 PPARG POMC MC4R GHRL AGRP
7 anorexia nervosa 32.7 POMC MC4R GHRL AGRP
8 glucose metabolism disease 31.6 PPARG POMC GHRL
9 acromegaly 31.6 POMC GNAS GHRL
10 maturity-onset diabetes of the young, type 1 30.8 PPARG NR0B2 ENPP1
11 obesity, early-onset, with adrenal insufficiency and red hair 12.7
12 morbid obesity and spermatogenic failure 12.6
13 obesity-hypoventilation syndrome 12.6
14 genetic obesity 12.5
15 mental retardation, truncal obesity, retinal dystrophy, and micropenis syndrome 12.5
16 obesity, hyperphagia, and developmental delay 12.5
17 abdominal obesity-metabolic syndrome 1 12.5
18 spastic paraplegia, intellectual disability, nystagmus, and obesity 12.5
19 retinal dystrophy and obesity 12.5
20 leptin deficiency or dysfunction 12.5
21 obesity due to congenital leptin deficiency 12.5
22 abdominal obesity-metabolic syndrome 3 12.5
23 wilms tumor, aniridia, genitourinary anomalies, mental retardation, and obesity syndrome 12.5
24 developmental delay, intellectual disability, obesity, and dysmorphism 12.5
25 hypothalamic obesity 12.4
26 hydrocephalus obesity hypogonadism 12.4
27 x-linked intellectual disability - short stature - obesity 12.4
28 body mass index quantitative trait locus 19 12.4
29 leptin receptor deficiency 12.3
30 body mass index quantitative trait locus 20 12.3
31 abdominal obesity-metabolic syndrome quantitative trait locus 2 12.3
32 aniridia - ptosis - intellectual disability - familial obesity 12.3
33 intellectual disability, epileptic seizures, hypogonadism and hypogenitalism, microcephaly, and obesity 12.3
34 rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome 12.2
35 coloboma-obesity-hypogenitalism-mental retardation syndrome 12.2
36 short stature-obesity syndrome 12.2
37 mental retardation, obesity, mandibular prognathism, and eye and skin anomalies 12.2
38 prolactin deficiency with obesity and enlarged testes 12.2
39 obesity due to congenital leptin resistance 12.2
40 severe early-onset obesity-insulin resistance syndrome due to sh2b1 deficiency 12.2
41 obesity due to sim1 deficiency 12.2
42 wilson-turner x-linked mental retardation syndrome 12.2
43 syndromic obesity 12.2
44 body mass index quantitative trait locus 9 12.2
45 body mass index quantitative trait locus 12 12.2
46 body mass index quantitative trait locus 4 12.2
47 cohen syndrome 12.2
48 body mass index quantitative trait locus 14 12.2
49 body mass index quantitative trait locus 8 12.2
50 body mass index quantitative trait locus 7 12.2

Graphical network of the top 20 diseases related to Body Mass Index Quantitative Trait Locus 11:



Diseases related to Body Mass Index Quantitative Trait Locus 11
Sources

Symptoms & Phenotypes for Body Mass Index Quantitative Trait Locus 11

About this section

Human phenotypes related to Body Mass Index Quantitative Trait Locus 11:

59 32 (show all 11)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 increased adipose tissue 59 32 obligate (100%) Obligate (100%) HP:0009126
2 polyphagia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002591
3 childhood-onset truncal obesity 59 32 frequent (33%) Frequent (79-30%) HP:0008915
4 hypertension 59 32 occasional (7.5%) Occasional (29-5%) HP:0000822
5 type ii diabetes mellitus 59 32 occasional (7.5%) Occasional (29-5%) HP:0005978
6 hypertriglyceridemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002155
7 acanthosis nigricans 59 32 occasional (7.5%) Occasional (29-5%) HP:0000956
8 hyperinsulinemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0000842
9 obesity 59 32 Obligate (100%) HP:0001513
10 decreased resting energy expenditure 32 HP:0012340
11 increased waist to hip ratio 32 HP:0031819

Clinical features from OMIM:

300306 601665

UMLS symptoms related to Body Mass Index Quantitative Trait Locus 11:


symptoms, high weight, obesity, metabolically benign, monogenic obesity

MGI Mouse Phenotypes related to Body Mass Index Quantitative Trait Locus 11:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.38 ADRB2 ADRB3 AGRP BRCA2 CARTPT DDHD2
2 growth/size/body region MP:0005378 10.36 ADRB2 ADRB3 AGRP BRCA2 CARTPT ENPP1
3 adipose tissue MP:0005375 10.32 ADRB2 ADRB3 AGRP CARTPT ENPP1 GHRL
4 behavior/neurological MP:0005386 10.31 ADRB2 ADRB3 AGRP BRCA2 CARTPT DDHD2
5 endocrine/exocrine gland MP:0005379 10.2 ADRB2 ADRB3 BRCA2 CARTPT GHRL GNAS
6 cardiovascular system MP:0005385 10.18 ADRB2 ENPP1 GLDC GNAS KCNH2 MC4R
7 immune system MP:0005387 10.07 ADRB2 BRCA2 CARTPT ENPP1 GNAS MC4R
8 nervous system MP:0003631 9.93 ADRB2 AGRP BRCA2 DDHD2 ENPP1 GLDC
9 liver/biliary system MP:0005370 9.92 AGRP ENPP1 GNAS MC4R NR0B2 POMC
10 neoplasm MP:0002006 9.8 BRCA2 GNAS MC4R POLG POMC PPARG
11 no phenotypic analysis MP:0003012 9.5 ADRB2 AGRP GNAS MC4R POLG POMC
12 skeleton MP:0005390 9.32 ADRB2 BRCA2 CARTPT ENPP1 GLDC GNAS
Sources

Drugs & Therapeutics for Body Mass Index Quantitative Trait Locus 11

About this section

DrugBank drugs 16 :

(show all 10)
# Drug Name Indication DrugBank ID
1 Amphetamine Amphetamine is indicated for the treatment of attention-deficit/hyperactivity disorders (ADHD) as well as for the treatment of central nervous system disorders such as narcolepsy.[A18540] ADHD is a complex disorder associated with the substantial heterogeneity in etiology, clinical presentation, and treatment outcome. ADHD comes from a complex interplay between interdependent genetic and non-genetic factors which cause complex mental disorders in children and teenagers.[A174271] On the other hand, narcolepsy is a chronic sleep disorder typically resenting during adolescence and characterized by excessive daytime sleepiness.[A174274] Amphetamine is also being used nowadays off-label for the treatment of obesity, depression and chronic pain.[A174268, A174283] DB00182
2 Benzphetamine For the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction DB00865
3 Bupropion Bupropion is indicated for the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation. When used in combination with [naltrexone] as the marketed product ContraveⓇ, bupropion is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 30 kg/m^2 or greater (obese) or 27 kg/m^2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). Bupropion is also used off-label as a first-line treatment in patients with ADHD and comorbid bipolar disorder when used as an adjunct to mood stabilizers.[F4624] DB01156
4 Fluoxetine Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present.[L7664] Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar I Disorder and treatment resistant depression.[L7664] DB00472
5 Liraglutide Liraglutide is indicated in combination with diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus[Label,L6718]. It is also indicated to reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus as well as cardiovascular disease[Label]. DB06655
6 Lorcaserin For the treatment of obesity, as an adjunct to a reduced-calorie diet and increased physical activity. DB04871
7 Naltrexone Used as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program. DB00704
8 Orlistat For obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. Also used to reduce the risk for weight regain after prior weight loss. Use of orlistat is pending revision due to reports of liver-related adverse events. DB01083
9 Phentermine Phentermine is indicated, alone or in combination with topiramate, as a short-term adjunct, not pass a few weeks, in a regimen of weight reduction based on exercise, behavioral modifications and caloric restriction in the management of exogenous obesity for patients with an initial body mass index (BMI) greater than 30 kg/m2 or greater than 27 kg/m2 in presence of other risk factors such as controller hypertension, diabetes or hyperlipidemia.[FDA label] Exogenous obesity is considered when the overweight is caused by consuming more food than the person activity level warrants. This condition commonly causes an increase in fat storage. It is an epidemic condition in the United States where over two-thirds of adults are overweight or obese and one in three Americans is obese. In the world, the incidence of obesity has nearly doubled.[A174391] DB00191
10 Pipradrol Used to manage fatigue [L2522] and depression [L2515], [A32724], [L2518], [L2523]. Used as an adjunct therapy in the management of obesity [L2522]. DB11584

Drugs for Body Mass Index Quantitative Trait Locus 11 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1224)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
2
Citalopram Approved Phase 4 59729-33-8 2771
3
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 441411 12560
4
Vancomycin Approved Phase 4 1404-90-6 441141 14969
5
Lixisenatide Approved Phase 4 320367-13-3
6
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3
7
Metyrapone Approved, Investigational Phase 4 54-36-4 4174
8
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
9
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
10
Ticagrelor Approved Phase 4 274693-27-5 9871419
11
Tolnaftate Approved, Investigational, Vet_approved Phase 4 2398-96-1 5510
12
Dapsone Approved, Investigational Phase 4 80-08-0 2955
13
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
14
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
15
Acetaminophen Approved Phase 4 103-90-2 1983
16
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
17
Meropenem Approved, Investigational Phase 4 119478-56-7, 96036-03-2 64778 441130
18
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
19
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
20
Adenosine Approved, Investigational Phase 4 58-61-7 60961
21
Dalteparin Approved Phase 4 9005-49-6
22
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
23
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
24
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
25
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
26
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
27
Enoxaparin Approved Phase 4 9005-49-6 772
28
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 5282452 6366718
29
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 130881 158781
30
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
31
Histamine Approved, Investigational Phase 4 51-45-6 774
32
Infliximab Approved Phase 4 170277-31-3
33
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
34
Racepinephrine Approved Phase 4 329-65-7 838
35
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
36
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
37
Nadroparin Approved, Investigational Phase 4
38
Memantine Approved, Investigational Phase 4 19982-08-2 4054
39
Tigecycline Approved Phase 4 220620-09-7 5282044
40
Lactulose Approved Phase 4 4618-18-2 11333
41
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
42
Ethambutol Approved Phase 4 74-55-5 3279 14052
43
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
44
Ziprasidone Approved Phase 4 146939-27-7 60854
45
Atenolol Approved Phase 4 29122-68-7 2249
46
Ferrous fumarate Approved Phase 4 141-01-5
47
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
48
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
49
Bilberry Approved, Experimental Phase 4
50
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883

Interventional clinical trials:

(show top 50) (show all 9874)
# Name Status NCT ID Phase Drugs
1 Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
2 Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass Unknown status NCT02952963 Phase 4 Chenodeoxycholic Acid;Colesevelam
3 The Effect of Obesity in Dexmedetomidine Metabolic Clearance Unknown status NCT02557867 Phase 4 Dexmedetomidine
4 The Effect of Moxonidine and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension: a Randomised, Double Blind, Active Comparator Clinical Trial Unknown status NCT01360710 Phase 4 Moxonidine;Irbesartan
5 Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Overweight and Obesity Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Control Study Unknown status NCT02999841 Phase 4 Acarbose;Vildagliptin
6 Assessment of the Effect of Moxonidine and Diet on Cardiac, Renal and Endothelial Function in Young Subjects With Abdominal Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
7 The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals Unknown status NCT01405352 Phase 4
8 Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery Unknown status NCT02310178 Phase 4
9 Effects of Chenodeoxycholic Acid and Colesevelam on GLP-1 Secretion, During a Meal, After Roux-en-Y Gastric Bypass Unknown status NCT02876484 Phase 4 Colesevelam;Chenodeoxycholic Acid
10 Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
11 A Study of the Pharmacokinetics of Dexmedetomidine in Morbid Obesity. Unknown status NCT01864187 Phase 4 Dexmedetomidine
12 Evaluation of the Effects of Laying Early (Between 12 and 16) a Gastric Band on the Prevention of Morbid Obesity in Late Adolescence. Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
13 Levonorgestrel-releasing Intrauterine Device Effects on Hemostatic and Arterial Function of Obese Women Unknown status NCT01320917 Phase 4
14 Prevention and Control of Obesity in Primary School Children in Tehran Unknown status NCT02082080 Phase 4
15 Prospective, Clinical Study of the Effect of Bariatric Surgery, Laparoscopic Sleeve Gastrectomy, on the Pharmacokinetics of Immunosuppressive Drugs in the Morbidly Obese, Kidney Transplant Candidate Unknown status NCT01913392 Phase 4
16 Healthy Opportunities for Physical Activity and Nutrition (HOP'N) After-School Project Unknown status NCT01015599 Phase 4
17 Impact of the Preservation of the Gastric Antrum in the Technique of Sleeve Gastrectomy for the Treatment of the Morbid Obesity: a Prospective,Controlled, Randomized, Multicentrique Study. Unknown status NCT01550601 Phase 4
18 Evaluation of Family Intervention Program for the Treatment of Overweight or Obese Children (Nereu Program): Randomized Clinical Trial Unknown status NCT01878994 Phase 4
19 Laparoscopic Roux-en-Y Gastric Bypass vs. Laparoscopic BPD-Duodenal Switch for Superobesity (BMI > 50 kg/m2)- A Randomized Clinical Trial Unknown status NCT00327912 Phase 4
20 Children's Healthy Living Program for Remote Underserved Minority Populations in the Pacific Region Unknown status NCT01881373 Phase 4
21 Prospective, Pharmacokinetic Study for Determination of the Relationship Between Lean Body Weight and Anti-Xa Activity 4 Hours After Subcutaneous Injection of 5700 IU Nadroparin in Morbidly Obese Patients After Bariatric Surgery. Unknown status NCT02295150 Phase 4 Nadroparin
22 Laparoscopic Bariatric Surgery: Impact of the Level of Neuromuscular Blockade on Surgical Conditions - Comparison Between Moderate and Deep Neuromuscular Blockade Unknown status NCT02118844 Phase 4 rocuronium
23 Beijing Chao-yang Hospital, Capital Medical University Unknown status NCT02583438 Phase 4 Saxagliptin (Bristol-Myers Squibb Company)
24 Randomisation to Endoluminal Intestinal Liner Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity) Unknown status NCT02055014 Phase 4 Liraglutide
25 Correlation of Postoperative VAS Values and Body Mass Index in Patients Undergoing Abdominal Surgery: A Clinical Trial Unknown status NCT02017314 Phase 4 Morphine
26 Laparoscopic Non Banded Vertical (Magenstrasse and Mill) Gastroplasty In Bariatric Surgery. Morbidity and Results on Weight Loss and Associated Co-morbidities Unknown status NCT02050477 Phase 4
27 Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
28 The Therapeutic Effect of Catgut Embedding in Obesity-A Randomized, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT02276235 Phase 4
29 Comparing the Efficacy of Two Frequently Used Doses of Enoxaparin for VTE Prophylaxis After Bariatric Surgery Unknown status NCT01970202 Phase 4 40mg Enoxaparin;60mg Enoxaparin
30 International, Multi Centre, Open, Prospective, Randomized Study: Banded Versus Conventional Laparoscopic Roux-en-Y (GABY) Unknown status NCT01015469 Phase 4
31 Influence of Erythromycin on ad Libitum Food Intake and the Evaluation of Motilin in Food Timing in Healthy Volunteers and Patients Unknown status NCT03024879 Phase 4 Erythromycin;Saline
32 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
33 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Unknown status NCT02959853 Phase 4 Anastrazole
34 Vitamin Deficiencies and Suppletion in Morbid Obesity Unknown status NCT02270749 Phase 4 Hydroxocobalamin;FitForMe vitamin B12
35 What is the Effects of Incretin on the Blood Pressure and Lipid in Overweight or Obese Diabetes Patients With Masked Hypertension: Liraglutide Plus Mitiglinide Comparing Metformin Plus Mitiglinide or Mitiglinide Alone（BLOOD STUDY） Unknown status NCT02503943 Phase 4 "Liraglutide" and "Mitiglinide";"Metformin" and "Mitiglinide";"Mitiglinide"
36 Prospective Randomized Study of Effects of Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy Unknown status NCT00667706 Phase 4
37 The Effect of Exenatide on Brown Adipose Tissue Activity and Energy Expenditure in Healthy Young Men Unknown status NCT03002675 Phase 4 Bydureon
38 Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass Unknown status NCT02374632 Phase 4
39 What is the Effects of Prokinetic Drug on the Blood Glucose in Type 2 Diabetes Patients: Mosapride Comparing Placebo Unknown status NCT02606617 Phase 4 Mosapride;Placebo
40 Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus Unknown status NCT00540462 Phase 4
41 The Effect of Mirabegron on Brown Adipose Tissue in Healthy Young White Caucasian and South Asian Men Unknown status NCT03012113 Phase 4 Mirabegron;Placebo Oral Capsule
42 Sildenafil Activates Browning of White Adipose and Improves Insulin Sensitivity in Human Adults Unknown status NCT02524184 Phase 4 sildenafil;placebo
43 Influence of the Aromatase Inhibitor Letrozole on Heart and Liver Function in Obese Men Unknown status NCT02097680 Phase 4 Letrozole;Placebo
44 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
45 Determining the Minimal Effective Volume (MEAV95) for Interscalene Brachial Plexus Block for Surgical Anesthesia Unknown status NCT01703130 Phase 4
46 Changes in Central Aortic Pressure, Endothelial Function and Biomarkers in African Americans With Cardiometabolic Syndrome: Comparison of Amlodipine/Olmesartan Versus Hydrochlorothiazide/Losartan Unknown status NCT01271374 Phase 4 amlodipine and olmesartan;losartan and HCTZ
47 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
48 Study of the Concentrations of Long Acting Morphine After Oral Absorption in Subjects Who Underwent Gastric Bypass (OBEMO 2) Unknown status NCT02641301 Phase 4 Sustained release morphine sulfate, 30 mg
49 The Research About the Influence of Medical Interventions in the Period of Insulin Resistance on Prevalence of Abnormal Glucose Tolerance Unknown status NCT02502344 Phase 4 Metformin
50 A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SUPPLEMENTATION WITH KIOLIC® IN PATIENTS WITH DIAGNOSIS OF METABOLIC SYNDROME TO IMPROVE ENDOTHELIAL FUNCTION AND INFLAMMATORY STATE. "KYMES" Unknown status NCT01168700 Phase 4 aged garlic extract;Placebo

Search NIH Clinical Center for Body Mass Index Quantitative Trait Locus 11

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Amphetamine
Benzphetamine
Benzphetamine
Benzphetamine hydrochloride
Bupropion
Dexfenfluramine
Dexfenfluramine Hydrochloride
Diethylpropion
Diethylpropion Hydrochloride
Fenfluramine
Fenfluramine Hydrochloride
Fluoxetine
Liraglutide
lorcaserin
Lorcaserin
lorcaserin hydrochloride
Mazindol
Methamphetamine
Naltrexone
orlistat
Orlistat
phendimetrazine
PHENDIMETRAZINE HYDROCHLORIDE
phendimetrazine tartrate
Phenmetrazine
Phenmetrazine Hydrochloride
Phentermine
Phentermine
Phentermine Hydrochloride
PHENTERMINE RESIN
Phenylpropanolamine
Phenylpropanolamine Hydrochloride
Pipradrol
sibutramine
SIBUTRAMINE HYDROCHLORIDE

Cochrane evidence based reviews: obesity

Sources

Genetic Tests for Body Mass Index Quantitative Trait Locus 11

About this section

Genetic tests related to Body Mass Index Quantitative Trait Locus 11:

# Genetic test Affiliating Genes
1 Obesity 29 ADRB2 ADRB3 AGRP CARTPT ENPP1 GHRL NR0B2 POMC PPARG SDC3 UCP3
2 Body Mass Index Quantitative Trait Locus 11 29
Sources

Anatomical Context for Body Mass Index Quantitative Trait Locus 11

About this section

MalaCards organs/tissues related to Body Mass Index Quantitative Trait Locus 11:

41
Liver, Heart, Breast, Brain, Testes, Kidney, Ovary
Sources

Publications for Body Mass Index Quantitative Trait Locus 11

About this section

Articles related to Body Mass Index Quantitative Trait Locus 11:

(show top 50) (show all 33383)
# Title Authors PMID Year
1
A PYY Q62P variant linked to human obesity. 9 38 71
16368708 2006
2
FTO Obesity Variant Circuitry and Adipocyte Browning in Humans. 38 71
26287746 2015
3
Functional characterization and structural modeling of obesity associated mutations in the melanocortin 4 receptor. 9 71
18801902 2009
4
Prevalence of melanocortin-4 receptor deficiency in Europeans and their age-dependent penetrance in multigenerational pedigrees. 9 71
18559663 2008
5
Variation in FTO contributes to childhood obesity and severe adult obesity. 38 71
17496892 2007
6
ENPP1 variants and haplotypes predispose to early onset obesity and impaired glucose and insulin metabolism in German obese children. 9 71
16968801 2006
7
Melanocortin 4 receptor mutations in a large cohort of severely obese adults: prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eating. 9 71
16507637 2006
8
Variants in the ghrelin gene are associated with metabolic syndrome in the Old Order Amish. 9 71
16204371 2005
9
Variants of ENPP1 are associated with childhood and adult obesity and increase the risk of glucose intolerance and type 2 diabetes. 9 71
16025115 2005
10
Ala67Thr polymorphism in the Agouti-related peptide gene is associated with inherited leanness in humans. 9 71
15054840 2004
11
The SLC6A14 gene shows evidence of association with obesity. 38 8
14660752 2003
12
Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. 9 71
12646665 2003
13
A polymorphism in the human agouti-related protein is associated with late-onset obesity. 9 71
12213871 2002
14
A missense mutation disrupting a dibasic prohormone processing site in pro-opiomelanocortin (POMC) increases susceptibility to early-onset obesity through a novel molecular mechanism. 9 71
12165561 2002
15
Mutations in the preproghrelin/ghrelin gene associated with obesity in humans. 9 71
11502844 2001
16
Mutations in the small heterodimer partner gene are associated with mild obesity in Japanese subjects. 9 71
11136233 2001
17
Studies of the synergistic effect of the Trp/Arg64 polymorphism of the beta3-adrenergic receptor gene and the -3826 A-->G variant of the uncoupling protein-1 gene on features of obesity and insulin resistance in a population-based sample of 379 young Danish subjects. 9 71
10999801 2000
18
Phenotypes in three pedigrees with autosomal dominant obesity caused by haploinsufficiency mutations in the melanocortin-4 receptor gene. 9 71
10577903 1999
19
Effects of mutations in the human uncoupling protein 3 gene on the respiratory quotient and fat oxidation in severe obesity and type 2 diabetes. 9 71
9769326 1998
20
The Trp64Arg polymorphism of the beta 3-adrenergic receptor gene is not associated with obesity or type 2 diabetes mellitus in a large population-based Caucasian cohort. 9 71
9709965 1998
21
Lack of association between the Trp64 Arg mutation in the beta 3-adrenergic receptor gene and obesity in Japanese men: a longitudinal analysis. 9 71
9100608 1997
22
A mutation of the beta 3-adrenergic receptor is associated with visceral obesity but decreased serum triglyceride. 9 71
9112025 1997
23
A major quantitative trait locus determining serum leptin levels and fat mass is located on human chromosome 2. 9 71
9054940 1997
24
Role of the beta 3-adrenergic receptor locus in obesity and noninsulin-dependent diabetes among members of Caucasian families with a diabetic sibling pair. 9 71
8954053 1996
25
The Trp64Arg mutation of the beta3 adrenergic receptor gene has no effect on obesity phenotypes in the Québec Family Study and Swedish Obese Subjects cohorts. 9 71
8903328 1996
26
Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. 9 71
7609750 1995
27
Obesity paradox in cardiovascular disease: where do we stand? 38 17
31118651 2019
28
Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. 71
19151714 2009
29
A functional variant of the adipocyte glycerol channel aquaporin 7 gene is associated with obesity and related metabolic abnormalities. 71
17351148 2007
30
Medical sequencing at the extremes of human body mass. 71
17357083 2007
31
Positive association of obesity with single nucleotide polymorphisms of syndecan 3 in the Korean population. 71
17018662 2006
32
A large-scale genetic association study of ossification of the posterior longitudinal ligament of the spine. 71
16609882 2006
33
No evidence for association of the ENPP1 (PC-1) K121Q variant with risk of type 2 diabetes in a Japanese population. 71
16607460 2006
34
Increased hepatic levels of the insulin receptor inhibitor, PC-1/NPP1, induce insulin resistance and glucose intolerance. 71
15677494 2005
35
CART peptide levels are altered by a mutation associated with obesity at codon 34. 71
15326462 2004
36
Effects of the Trp64Arg polymorphism in the beta3-adrenergic receptor gene on insulin sensitivity in small for gestational age neonates. 71
15472194 2004
37
Polymorphisms in the amino acid transporter solute carrier family 6 (neurotransmitter transporter) member 14 gene contribute to polygenic obesity in French Caucasians. 8
15331564 2004
38
The association of the K121Q polymorphism of the plasma cell glycoprotein-1 gene with type 2 diabetes and hypertension depends on size at birth. 71
15126519 2004
39
The PC-1 Q121 allele is exceptionally prevalent in the Dominican Republic and is associated with type 2 diabetes. 71
15001634 2004
40
A genome-wide scan for childhood obesity-associated traits in French families shows significant linkage on chromosome 6q22.31-q23.2. 71
14988267 2004
41
Genetic polymorphism PC-1 K121Q and ethnic susceptibility to insulin resistance. 71
14671192 2003
42
Association of the mitochondrial DNA 15497G/A polymorphism with obesity in a middle-aged and elderly Japanese population. 71
12905068 2003
43
Ghrelin gene: identification of missense variants and a frameshift mutation in extremely obese children and adolescents and healthy normal weight students. 71
12050239 2002
44
Structure and receptor binding of PYY analogs. 71
11825645 2002
45
Nucleotide pyrophosphatase gene polymorphism associated with ossification of the posterior longitudinal ligament of the spine. 71
11771660 2002
46
The Q121 PC-1 variant and obesity have additive and independent effects in causing insulin resistance. 71
11739459 2001
47
The gene structure and minimal promoter of the human agouti related protein. 71
11602360 2001
48
Mutational screening of the CART gene in obese children: identifying a mutation (Leu34Phe) associated with reduced resting energy expenditure and cosegregating with obesity phenotype in a large family. 71
11522684 2001
49
Insulin response to glucose is lower in individuals homozygous for the Arg 64 variant of the beta-3-adrenergic receptor. 71
11095426 2000
50
Genome-wide scan of obesity in Finnish sibpairs reveals linkage to chromosome Xq24. 8
10999806 2000